**Morphology based diagnosis with Pap cytology is subject to interpretive variability and lacks diagnostic accuracy**

*HPV DNA testing is the most sensitive screening method, but diagnostic accuracy improves with triage testing of HPV+ test results*

---

**Using objective biomarkers to triage can help alleviate diagnostic uncertainty**

*The CINtec® PLUS Cytology test uses two objective biomarkers to answer the question: Are oncogenically transformed cells present in the HPV positive woman?*

In healthy cells, p16 and Ki-67 expression is mutually exclusive.

---

**CINtec® PLUS Cytology test gives a simple, objective answer**

*Risk of 12 other hrHPV (+) women to develop CIN3+ in 3 years*
**cobas® HPV Test with CINtec® PLUS Cytology triage could lead to improved clinical outcomes**

- Clinicians use screening and triage test to identify the risk of disease and can manage women based on their level of risk.
- Various combinations of screening and triage tests can result in differences in disease detection and the number of colposcopies required.
- A strategy that results in more disease detection without increasing the colposcopy rate can aid clinicians making decisions that result in improved clinical outcomes and lower healthcare costs.

**Triage with CINtec® PLUS Cytology provides greater assurance of safety**

**Improved risk stratification and retest threshold of HPV+ women**

**Health Economic Model**

<table>
<thead>
<tr>
<th>Cervical cancer detection rate</th>
<th>Total cost per screened patient (€)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pap Cytology</td>
<td>€54.3M</td>
</tr>
<tr>
<td>cobas® HPV Test with CINtec® PLUS Cytology triage*</td>
<td>€10.66</td>
</tr>
</tbody>
</table>


*cobas® HPV 16/18 genotyping and CINtec® PLUS Cytology triage of 12 other hrHPV women

**Benefits of CINtec® PLUS Cytology**

- Greater disease detection
- Safety assurance of a negative result: Never exceeded colposcopy referral threshold
- The authors suggest safe extension of the testing interval: CINtec® PLUS Cytology (3 years) versus Pap Cytology (1 year)

**CINtec® PLUS Cytology:**

- Gives physicians simple, actionable results to be more confident in patient management
- Increases the efficiency of disease detection in the first round of screening
- Provides women with clear answers and more certainty in their test results
CINtec® PLUS Cytology, part of The Roche Cervical Cancer Portfolio. Find the focus you need to make decisions for each of your patients with confidence, certainty and conclusiveness. Using Roche’s three clinically validated tests in powerful combination helps stratify women at risk and improves detection and confirmation of high-grade disease in the first round of testing.

be confident

Screen with cobas® HPV, the only FDA-approved and CE-IVD marked test for first-line primary screening in both major collection media. cobas® HPV delivers 3-in-1 results with detection of 14 hrHPV genotypes and simultaneous, individual results for HPV 16 and HPV 18 for actionable patient management.

be certain

Triage with CINtec® PLUS Cytology, the only test that uses dual-biomarker technology to simultaneously detect p16 and Ki-67 to provide a strong indicator of the presence of transforming HPV infection.

be conclusive

Diagnose with CINtec® Histology – Enhances identification of occult lesions that may be missed by H&E or morphologic interpretation alone.

Learn more about CINtec® PLUS Cytology by contacting your local Roche representative.

© 2019 Roche. COBAS and CINTEC are trademarks of Roche. Published by: Ventana Medical Systems, Inc. 1910 E. Innovation Park Drive Tucson, AZ 85755 USA cervicalbiomarkers.com